Exploring the Advancements and Efficacies of Targeted Therapy in Oncology: A Comprehensive Review for Healthcare Professionals
OthersPage Navigation
Introduction
Targeted therapy, a modern cornerstone in cancer treatment, has significantly transformed oncology outcomes. By specifically interacting with molecular targets associated with cancer, it offers a more precise and effective approach compared to traditional therapies.
Evolution of Targeted Therapy
From monoclonal antibodies to small molecule inhibitors, the evolution of targeted therapies has been remarkable. Monoclonal antibodies, such as trastuzumab and rituximab, have proven effective against HER2-positive breast cancer and non-Hodgkin lymphoma respectively. Small molecule inhibitors, like imatinib, have revolutionized the treatment of chronic myeloid leukemia by inhibiting BCR-ABL tyrosine kinase.
Current Advancements
Recent advancements include the development of immune checkpoint inhibitors, CAR-T cell therapy, and the use of poly (ADP-ribose) polymerase (PARP) inhibitors. These therapies have shown promising results in various malignancies, including lung cancer, melanoma, and ovarian cancer.
Efficacies of Targeted Therapies
Targeted therapies have demonstrated improved survival rates, reduced side effects, and enhanced patient quality of life. However, resistance to these therapies remains a significant challenge. Ongoing research aims to overcome this through combination therapies and novel drug development.
Conclusion
Targeted therapy has revolutionized oncology, offering hope to patients who previously had limited treatment options. As our understanding of cancer biology expands, so too will the scope and efficacy of targeted therapies. It is crucial that healthcare professionals stay updated on these advancements to provide optimal patient care.
Recommended News For You
Recommended Articles For You
Featured News
Featured Articles
Featured Events
Featured KOL Videos
1.
On all CAR-T products, the FDA is calling for a new boxed warning.
2.
Video: Liver transplant for patients with advanced colorectal cancer
3.
Asymptomatic Brain Metastases in EGFR-Mutant NSCLC
4.
Healthcare AI, Meant to Save Money, Turns Out to Require a Lot of Expensive Humans
5.
Durvalumab Plus BCG Earns FDA Nod for Bladder Cancer
1.
A Closer Look at Breast Cancer: Examining the Ultrasound Images
2.
RIBOTAC Therapy for Oncogenic RNA: A Paradigm Shift in Targeted Cancer Treatment
3.
Monitoring Delayed Toxicity of Antibody Therapies
4.
Emerging Therapies Through Immune-Engineered Blood Cell Manufacturing
5.
What You Need To Know About Secondary Polycythemia: Treatment & Symptoms
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients
2.
Learning About Different Treatment Approaches For Acute Lymphoblastic Leukemia
3.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II
4.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part V
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Welcome to Hidoc Dr.
Join to enhance your clinical skills and gain specialized in-depth medical knowledge